|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
4/8/2008 8:44:45 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has extended the subsequent offering period of its tender offer for all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) to 5:00 p.m., New York City time, on April 14, 2008. Pursuant to the tender offer, Explorer Acquisition Corp. is offering to purchase shares of Encysive at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes. The subsequent offering period had been previously scheduled to expire at 5:00 p.m., New York City time, on April 7, 2008. According to the depositary for the offer, a total of 67,435,726 shares (representing approximately 83.3% of the outstanding shares), had been tendered prior to such time.
|
|
|
|
|
|
|
|
|
|
|